{"transactions":[{"id":1304347,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":84192,"kind":"person","name":"Smith Bryan E.","position":1,"cik":"0001748041","reported_name":"Smith Bryan E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel, Corporate Sec"}}],"security":"Restricted Stock Units","published_at":"2025-01-13T17:30:06.000Z","date":"2025-01-10","kind":"grant","planned":false,"acquired":true,"shares":64500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's common stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents shares issuable on settlement of restricted stock units (\"RSUs\"). The RSUs will vest with respect to 50% of the RSUs on January 10, 2027, and then with respect to the remaining 50% of the underlying shares on January 10 2028, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Represents shares issuable on settlement of restricted stock units (\"RSUs\"). The RSUs will vest with respect to 50% of the RSUs on January 10, 2027, and then with respect to the remaining 50% of the underlying shares on January 10 2028, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer."}],"balance_after":64500,"derivative":{"underlying":"Common Stock","underlying_shares":64500},"source":{"system":"sec-edgar","filing":"0000950170-25-004921","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1748041/000095017025004921/ownership.xml","form_type":"4"}},{"id":1304346,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":84192,"kind":"person","name":"Smith Bryan E.","position":1,"cik":"0001748041","reported_name":"Smith Bryan E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel, Corporate Sec"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-13T17:30:06.000Z","date":"2025-01-10","kind":"grant","planned":false,"acquired":true,"shares":150500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase up to 150,000 shares of common stock, which option vests with respect to 37,625 shares on January 10, 2026, and then with respect to 6.25% of the underlying shares quarterly over the three-year period ending January 10, 2029, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer."}],"balance_after":150500,"derivative":{"exercise_price":4.04,"expiration_date":"2035-01-10","underlying":"Common Stock","underlying_shares":150500},"source":{"system":"sec-edgar","filing":"0000950170-25-004921","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1748041/000095017025004921/ownership.xml","form_type":"4"}},{"id":1354395,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":84192,"kind":"person","name":"Smith Bryan E.","position":1,"cik":"0001748041","reported_name":"Smith Bryan E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel, Corporate Sec"}}],"security":"Stock Option (right to buy)","published_at":"2024-11-22T17:00:06.000Z","date":"2024-11-21","kind":"grant","planned":false,"acquired":true,"shares":474350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This transaction represents the attainment of the performance conditions applicable to an option award subject to both performance-based and time-based vesting criteria granted to the reporting person on May 1, 2023. The option was determined to satisfy the performance-based vesting criteria with respect to 474,350 shares of underlying Common Stock on November 21, 2024 and time-based vesting criteria with respect to 177,881 shares of underlying Common Stock on November 1, 2024. The option will satisfy the time-based vesting criteria with respect to the 296,469 remaining shares of Common Stock underlying the option in substantially equal quarterly installments over a three-year period ending May 1, 2027."}],"balance_after":474350,"derivative":{"exercise_price":2.3,"expiration_date":"2033-05-01","underlying":"Common Stock","underlying_shares":474350},"source":{"system":"sec-edgar","filing":"0000950170-24-130278","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1748041/000095017024130278/ownership.xml","form_type":"4"}},{"id":1479082,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":84192,"kind":"person","name":"Smith Bryan E.","position":1,"cik":"0001748041","reported_name":"Smith Bryan E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel, Corporate Sec"}}],"security":"Stock Option (right to buy)","published_at":"2024-06-14T17:00:03.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":241650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This transaction represents the attainment of the performance conditions applicable to an option award subject to both performance-based and time-based vesting criteria granted to the reporting person on May 1, 2023. The option was determined to satisfy the performance-based vesting criteria with respect to 241,650 shares of underlying Common Stock on June 13, 2024 and time-based vesting criteria with respect to 60,413 shares of underlying Common Stock on May 1, 2024. The option will satisfy the time-based vesting criteria with respect to the 181,237 remaining shares of Common Stock underlying the option in substantially equal quarterly installments over a three-year period ending May 1, 2027."}],"balance_after":241650,"derivative":{"exercise_price":2.3,"expiration_date":"2033-05-01","underlying":"Common Stock","underlying_shares":241650},"source":{"system":"sec-edgar","filing":"0000950170-24-073767","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1748041/000095017024073767/ownership.xml","form_type":"4"}},{"id":1908392,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":84192,"kind":"person","name":"Smith Bryan E.","position":1,"cik":"0001748041","reported_name":"Smith Bryan E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel, Corporate Sec"}}],"security":"Stock Option (right to buy)","published_at":"2023-05-02T18:50:38.000Z","date":"2023-05-01","kind":"grant","planned":false,"acquired":true,"shares":179000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase up to 179,000 shares of Common Stock, which option vests with respect to 44,750 shares on May 1, 2024, and then with respect to 6.25% of the underlying shares quarterly over the three-year period ending May 1, 2027."}],"balance_after":179000,"derivative":{"exercise_price":2.3,"expiration_date":"2033-05-01","underlying":"Common Stock","underlying_shares":179000},"source":{"system":"sec-edgar","filing":"0001209191-23-026734","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1748041/000120919123026734/doc4.xml","form_type":"4"}},{"id":2036283,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":84192,"kind":"person","name":"Smith Bryan E.","position":1,"cik":"0001748041","reported_name":"Smith Bryan E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel, Corporate Sec"}}],"security":"Stock Option (right to buy)","published_at":"2023-02-02T17:43:57.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":155000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase up to 155,000 shares of Common Stock, which option vests with respect to 38,750 shares on February 1, 2024, and then with respect to 6.25% of the underlying shares quarterly over the three-year period ending February 1, 2027."}],"balance_after":155000,"derivative":{"exercise_price":3.08,"expiration_date":"2033-02-01","underlying":"Common Stock","underlying_shares":155000},"source":{"system":"sec-edgar","filing":"0001209191-23-006309","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1748041/000120919123006309/doc4.xml","form_type":"4"}},{"id":2416848,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":84192,"kind":"person","name":"Smith Bryan E.","position":1,"cik":"0001748041","reported_name":"Smith Bryan E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel, Corporate Sec"}}],"security":"Stock Option (right to buy)","published_at":"2022-02-02T17:37:52.000Z","date":"2022-02-01","kind":"grant","acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase up to 120,000 shares of Common Stock, which option vests with respect to 30,000 shares on February 1, 2023, and then with respect to 6.25% of the underlying shares quarterly over the three-year period ending February 1, 2026."}],"balance_after":120000,"derivative":{"exercise_price":3.97,"expiration_date":"2032-02-01","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0001209191-22-006489","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1748041/000120919122006489/doc4.xml","form_type":"4"}},{"id":2730386,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":84192,"kind":"person","name":"Smith Bryan E.","position":1,"cik":"0001748041","reported_name":"Smith Bryan E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-04T16:27:12.000Z","date":"2021-05-03","kind":"grant","acquired":true,"shares":158500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase up to 158,500 shares of Common Stock, which option vests with respect to 39,625 shares on May 3, 2022, and then with respect to 6.25% of the underlying shares quarterly over the three year period ending May 3, 2025."}],"balance_after":158500,"derivative":{"exercise_price":9.91,"expiration_date":"2031-05-03","underlying":"Common Stock","underlying_shares":158500},"source":{"system":"sec-edgar","filing":"0000899243-21-018105","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1748041/000089924321018105/doc4.xml","form_type":"4"}},{"id":2766544,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":84192,"kind":"person","name":"Smith Bryan E.","position":1,"cik":"0001748041","reported_name":"Smith Bryan E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"GC/Urovant Sciences, Inc."}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-31T12:30:26.000Z","date":"2021-03-29","kind":"disposition_to_issuer","acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon consummation of the Merger, each option to purchase Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had an exercise price per Common Share that is less than $16.25 was cancelled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such option that is equal to the difference between $16.25 and the per share exercise price of such option, without interest and less any applicable withholding for taxes, as described in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":6.88,"expiration_date":"2029-01-06","underlying":"Common Shares","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-21-014103","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1748041/000089924321014103/doc4.xml","form_type":"4"}},{"id":2766543,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":84192,"kind":"person","name":"Smith Bryan E.","position":1,"cik":"0001748041","reported_name":"Smith Bryan E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"GC/Urovant Sciences, Inc."}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-31T12:30:26.000Z","date":"2021-03-29","kind":"disposition_to_issuer","acquired":false,"shares":3500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon consummation of the Merger, each option to purchase Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had an exercise price per Common Share that is less than $16.25 was cancelled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such option that is equal to the difference between $16.25 and the per share exercise price of such option, without interest and less any applicable withholding for taxes, as described in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":13.65,"expiration_date":"2028-10-14","underlying":"Common Shares","underlying_shares":3500},"source":{"system":"sec-edgar","filing":"0000899243-21-014103","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1748041/000089924321014103/doc4.xml","form_type":"4"}},{"id":2766542,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":84192,"kind":"person","name":"Smith Bryan E.","position":1,"cik":"0001748041","reported_name":"Smith Bryan E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"GC/Urovant Sciences, Inc."}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-31T12:30:26.000Z","date":"2021-03-29","kind":"disposition_to_issuer","acquired":false,"shares":93450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon consummation of the Merger, each option to purchase Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had an exercise price per Common Share that is less than $16.25 was cancelled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such option that is equal to the difference between $16.25 and the per share exercise price of such option, without interest and less any applicable withholding for taxes, as described in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":7.53,"expiration_date":"2028-05-20","underlying":"Common Shares","underlying_shares":93450},"source":{"system":"sec-edgar","filing":"0000899243-21-014103","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1748041/000089924321014103/doc4.xml","form_type":"4"}},{"id":2766541,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":84192,"kind":"person","name":"Smith Bryan E.","position":1,"cik":"0001748041","reported_name":"Smith Bryan E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"GC/Urovant Sciences, Inc."}}],"security":"Common Shares","published_at":"2021-03-31T12:30:26.000Z","date":"2021-03-29","kind":"disposition_to_issuer","acquired":false,"shares":115106,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Immediately prior to the consummation of the Merger, these securities were time-based restricted share units (\"RSUs\") subject to vesting and previously granted pursuant to the Issuer's 2017 Equity Incentive Plan.  Upon the consummation of the Merger, each RSU, whether vested or unvested, that had not been settled in Common Shares prior to the effective time of the Merger was canceled and converted automatically into the right to receive $16.25 per each such RSU, without interest and less any applicable withholding for taxes, as described in the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the consummation of the Merger, each outstanding common share of the Issuer (\"Common Share\") was cancelled and converted into the right to receive $16.25 per share in cash, without interest and less any applicable withholding for taxes, as described in the Merger Agreement."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-014103","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1748041/000089924321014103/doc4.xml","form_type":"4"}},{"id":2766540,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":84192,"kind":"person","name":"Smith Bryan E.","position":1,"cik":"0001748041","reported_name":"Smith Bryan E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"GC/Urovant Sciences, Inc."}}],"security":"Common Shares","published_at":"2021-03-31T12:30:26.000Z","date":"2021-03-29","kind":"disposition_to_issuer","acquired":false,"shares":9341,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the consummation of the Merger, each outstanding common share of the Issuer (\"Common Share\") was cancelled and converted into the right to receive $16.25 per share in cash, without interest and less any applicable withholding for taxes, as described in the Merger Agreement."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-014103","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1748041/000089924321014103/doc4.xml","form_type":"4"}},{"id":2912361,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":84192,"kind":"person","name":"Smith Bryan E.","position":1,"cik":"0001748041","reported_name":"Smith Bryan E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"GC/Urovant Sciences, Inc."}}],"security":"Common Shares","published_at":"2021-01-08T18:29:17.000Z","date":"2021-01-07","kind":"tax_withholding","acquired":false,"shares":4761,"price":16.09,"value":76604.49,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock withheld by the Issuer to pay tax withholding obligations of the Reporting Person upon the vesting of restricted stock units previously granted to the Reporting Person."}],"balance_after":124447,"source":{"system":"sec-edgar","filing":"0001209191-21-002817","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1748041/000120919121002817/doc4.xml","form_type":"4"}},{"id":3163801,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":84192,"kind":"person","name":"Smith Bryan E.","position":1,"cik":"0001748041","reported_name":"Smith Bryan E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"GC/Urovant Sciences, Inc."}}],"security":"Common Shares","published_at":"2020-05-04T16:55:36.000Z","date":"2020-05-01","kind":"grant","acquired":true,"shares":77606,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"25% of the Restricted Stock Units shall vest on May 1, 2021; the remaining Restricted Stock Units vest in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer through each such vesting date."}],"balance_after":127606,"source":{"system":"sec-edgar","filing":"0001209191-20-026841","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1748041/000120919120026841/doc4.xml","form_type":"4"}},{"id":3256693,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":84192,"kind":"person","name":"Smith Bryan E.","position":1,"cik":"0001748041","reported_name":"Smith Bryan E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"GC/Urovant Sciences, Inc."}}],"security":"Stock Option (Right to Buy)","published_at":"2020-02-21T18:42:37.000Z","date":"2020-02-19","kind":"exercise","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All of the shares underlying this option are vested and exercisable as of the date hereof."}],"balance_after":20000,"derivative":{"exercise_price":6.88,"expiration_date":"2029-01-06","underlying":"Common Shares","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-20-005516","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1748041/000089924320005516/doc4.xml","form_type":"4"}},{"id":3256692,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":84192,"kind":"person","name":"Smith Bryan E.","position":1,"cik":"0001748041","reported_name":"Smith Bryan E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"GC/Urovant Sciences, Inc."}}],"security":"Common Shares","published_at":"2020-02-21T18:42:37.000Z","date":"2020-02-19","kind":"other","acquired":false,"shares":15165,"price":13.08,"value":198358.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the sale of 15,165 shares of common stock to Sumitovant Biopharma Ltd., a subsidiary of Dainippon Sumitomo Pharma, in a privately-negotiated transaction."}],"balance_after":50000,"source":{"system":"sec-edgar","filing":"0000899243-20-005516","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1748041/000089924320005516/doc4.xml","form_type":"4"}},{"id":3256691,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":84192,"kind":"person","name":"Smith Bryan E.","position":1,"cik":"0001748041","reported_name":"Smith Bryan E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"GC/Urovant Sciences, Inc."}}],"security":"Common Shares","published_at":"2020-02-21T18:42:37.000Z","date":"2020-02-19","kind":"tax_withholding","acquired":false,"shares":34835,"price":13.08,"value":455641.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents 26,300 shares surrendered to the Issuer in satisfaction of payment of exercise price and 8,535 shares surrendered to the Issuer in satisfaction of the payment of required withholding taxes in connection with the exercise of stock options."}],"balance_after":65165,"source":{"system":"sec-edgar","filing":"0000899243-20-005516","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1748041/000089924320005516/doc4.xml","form_type":"4"}},{"id":3256690,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":84192,"kind":"person","name":"Smith Bryan E.","position":1,"cik":"0001748041","reported_name":"Smith Bryan E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"GC/Urovant Sciences, Inc."}}],"security":"Common Shares","published_at":"2020-02-21T18:42:37.000Z","date":"2020-02-19","kind":"exercise","acquired":true,"shares":50000,"price":6.88,"value":344000.0,"ownership":{"direct":true},"balance_after":100000,"source":{"system":"sec-edgar","filing":"0000899243-20-005516","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1748041/000089924320005516/doc4.xml","form_type":"4"}},{"id":3314571,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":84192,"kind":"person","name":"Smith Bryan E.","position":1,"cik":"0001748041","reported_name":"Smith Bryan E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"GC/Urovant Sciences, Inc."}}],"security":"Common Shares","published_at":"2020-01-09T16:30:47.000Z","date":"2020-01-07","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"25% of the Restricted Stock Units shall vest on January 7, 2021; the remaining Restricted Stock Units vest in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer through each such vesting date."}],"balance_after":50000,"source":{"system":"sec-edgar","filing":"0000899243-20-000881","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1748041/000089924320000881/doc4.xml","form_type":"4"}},{"id":3700503,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":84192,"kind":"person","name":"Smith Bryan E.","position":1,"cik":"0001748041","reported_name":"Smith Bryan E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"GC/Urovant Sciences, Inc."}}],"security":"Stock Option (Right to Buy)","published_at":"2019-01-08T17:23:29.000Z","date":"2019-01-06","kind":"grant","acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the total shares underlying the option shall vest and become exercisable on January 2, 2020; the remaining shares vest in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer through each such vesting date."}],"balance_after":70000,"derivative":{"exercise_price":6.88,"expiration_date":"2029-01-06","underlying":"Common Shares","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0000899243-19-000778","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1748041/000089924319000778/doc4.xml","form_type":"4"}},{"id":3788597,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":84192,"kind":"person","name":"Smith Bryan E.","position":1,"cik":"0001748041","reported_name":"Smith Bryan E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"GC of Urovant Sciences,Inc."}}],"security":"Stock Option (Right to Buy)","published_at":"2018-10-17T18:10:45.000Z","date":"2018-10-15","kind":"grant","acquired":true,"shares":3500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the total shares underlying the option shall vest and become exercisable on October 1, 2019; the remaining shares vest in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer through each such vesting date."}],"balance_after":3500,"derivative":{"exercise_price":13.65,"expiration_date":"2028-10-14","underlying":"Common Shares","underlying_shares":3500},"source":{"system":"sec-edgar","filing":"0001209191-18-055414","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1748041/000120919118055414/doc4.xml","form_type":"4"}}]}